ArticleNature communications2020
Somatic SF3B1 hotspot mutation in prolactinomas.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 80 citations in OpenAlex.
- Prolactinomas in the transition from adolescence to young adulthood: A multicentre, retrospective study from the TALENT group.Journal of neuroendocrinology · 2026Observational
- Genomic characterization of aggressiveness in pituitary neuroendocrine tumors.Neuro-oncology · 2026Article
- Genetic testing in pituitary adenomas: a Pituitary Society International Consensus Statement.Nature reviews. Endocrinology · 2026Review
- The Role of Splicing Machinery as a Promising Potential Therapeutic Target for Pituitary Neuroendocrine Tumors (PitNETs).Cancers · 2026Review
- Role of alternative splicing in cancer progression.Irish journal of medical science · 2026Review
- Determinants of remission and recurrence following transsphenoidal surgery for prolactinoma: a single-center experience.Pituitary · 2026Article
- Aggressive and malignant pituitary tumours: does the sex matter?Pituitary · 2026Review
- Molecular biology of pituitary neuroendocrine tumors.Journal of neuro-oncology · 2026Review
- The Differences Between Dopamine Agonist-Resistant and -Non-Resistant Prolactinomas: Are There Any Predictors of a Good Response?Biomedicines · 2026Article
- New Insights from the Expression of the Mismatch Repair System in Pituitary Neuroendocrine Tumors.Endocrine pathology · 2026Article
- Splicing factor FUS facilitates the progression of PIT1-lineage PitNETs by upregulating MDM2.Theranostics · 2026Article
- An MRI radiomics approach using invasion-based weak supervision for identifying and evaluating aggressive PitNETs.NPJ digital medicine · 2025Article
- Sexual dimorphism in pituitary neuroendocrine tumours.Nature reviews. Endocrinology · 2025Article
- Non-recurrent mutations and copy number changes predominate pituitary adenoma genomes.European journal of endocrinology · 2025Article
- Liquid Biopsy in Pituitary Neuroendocrine Tumors-Potential Biomarkers for Diagnosis, Prognosis, and Therapy.International journal of molecular sciences · 2025Review
- Somatic Activating ESR1 Mutation in an Aggressive Prolactinoma.The Journal of clinical endocrinology and metabolism · 2025Article
- Grading and staging for pituitary neuroendocrine tumors.Brain pathology (Zurich, Switzerland) · 2025Review
- Potential antitumoral effects of SRPK1 inhibition through modulation of VEGF splicing in pituitary somatotroph tumoral cells.Frontiers in endocrinology · 2025Article
- The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors.Brain pathology (Zurich, Switzerland) · 2025Review
- Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors.Acta neuropathologica · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 5 institutions in 2 countries.
Chuzhong Li *Department of Cell Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.ORCID http://orcid.org/0000-0002-8468-8249
Weiyan Xie *Department of Cell Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.ORCID http://orcid.org/0000-0001-6029-8521
Jared S RosenblumNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0001-5941-9082
Jianyu ZhouBioinformatics Division, Department of Computer Science and Technology, BNRIST, Tsinghua University, Beijing, 100084, China.
Jing GuoDepartment of Cell Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Yazhou MiaoDepartment of Cell Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Yutao ShenDepartment of Cell Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Hongyun WangDepartment of Cell Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Lei GongDepartment of Cell Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Mingxuan LiDepartment of Cell Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Sida ZhaoDepartment of Cell Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Sen ChengDepartment of Cell Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Haibo ZhuDepartment of Cell Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Tao JiangBioinformatics Division, Department of Computer Science and Technology, BNRIST, Tsinghua University, Beijing, 100084, China.ORCID http://orcid.org/0000-0003-3833-4498
Shiying LingDepartment of Neurosurgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei, 230001, China.
Fei WangDepartment of Neurosurgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei, 230001, China.
Hongwei ZhangDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Mingshan ZhangDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Yanming QuDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Qi ZhangNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Guilin LiDepartment of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Junmei WangDepartment of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Jun MaDepartment of Neuroimaging, Beijing Tiantan Hospital affiliated to Capital Medical University, Beijing, 100070, China.
Zhengping ZhuangNeuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. zhengping.zhuang@nih.gov.ORCID http://orcid.org/0000-0002-0009-7370
Yazhuo ZhangDepartment of Cell Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China. zhangyazhuo@ccmu.edu.cn.ORCID http://orcid.org/0000-0002-5290-4314
Capital Medical University · CNNational Institutes of Health · USUniversity of Science and Technology of China · CNTsinghua University · CNUniversity of California, Riverside · US
Funding
Hypoxia signaling in cancer developmentZIABC011773 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ZHUANG, ZHENGPING · 2017 to 2025
$13.0MEffect of Prazosin on Alcohol Craving, Stress Dysregulation and Alcohol RelapseR01AA020504 · NIAAA · YALE UNIVERSITY · PI FOX, HELEN CECILIA, SINHA, RAJITA · 2012 to 2016
$2.7MNIAAA NIH HHS R01 AA020504
Abstract
The genetic basis and corresponding clinical relevance of prolactinomas remain poorly understood. Here, we perform whole genome sequencing (WGS) on 21 patients with prolactinomas to detect somatic mutations and then validate the mutations with digital polymerase chain reaction (PCR) analysis of tissue samples from 227 prolactinomas. We identify the same hotspot somatic mutation in splicing factor 3 subunit B1 (SF3B1
Indexed as
AdultFemaleHumansMaleMutationPhosphoproteinsProgression-Free SurvivalProlactinProlactinomaReceptors, EstrogenRNA Splicing FactorsTranscription Factor Pit-1Young AdultESRRG protein, humanPhosphoproteinsProlactinReceptors, EstrogenRNA Splicing FactorsSF3B1 protein, humanTranscription Factor Pit-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.